Investment
Features
FeesSafety
Academy
More
Pluang+

Roscan Gold to join Gentile Mining Investor Forum in London, showcasing its Kandiole Gold Project progress.

Market News
18 Sep 2026
Newsfile Corp
View Source
Bullish
Roscan Gold to join Gentile Mining Investor Forum in London, showcasing its Kandiole Gold Project progress.

Roscan Gold Corporation will participate in the first Gentile Mining Investor Forum in London on October 19, 2026, an event designed to connect mining companies with investors. The forum, organized by Michael Gentile and Amvest Capital, will feature over 20 mining companies and provide opportunities for one-on-one meetings with investors. Roscan Gold aims to highlight its recent developments and future plans for the Kandiole Gold Project in Mali. This event offers Roscan Gold a platform to engage with a global network of investors and potentially attract further investment for its exploration activities in West Africa.

Roscan Gold's participation in the Gentile Mining Investor Forum in London is presented here with Pluang's Basic Materials sector data for context. As of Sep 18, 2026 17:42 WIB, 24 of 33 US Basic Materials stocks on Pluang rose while 9 fell. Kinross Gold Corporation (KGC) traded at USD 28.92 with a 1.56% gain and 99% buy orders, contrasting with MP Materials (MP) at USD 50.14 and 83% buy orders, and Agnico Eagle Mines Ltd (AEM) at USD 204.27 with 100% buy orders and the longest typical hold time of 55 days on Pluang.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
26 minutes ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App